The Latest Cardiac and Vascular News
Adds FDA-cleared AI analysis to Wellysis’ S-Patch ECG monitoring solution, expanding its capabilities beyond ECG acquisition Enables FDA-cleared AI analysis of S-Patch ECG data to be integrated into third-party ECG platforms and existing clinical workflows Designed to streamline ECG…
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly’s TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular ima
HOUSTON–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has accepted XCath’s Iris Surgical Robotic System into its Total Product Life Cycle Advisory Program (TAP) Pilot, the company announced today. The system is intended for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. XCath is a medical device company advancing endovascular surgical robotics, and the FDA’s decision comes after it granted Breakthrough Device Designation to the Iris Syste
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ — Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase…
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 2027 First Quarter Financial Highlights Quarter Ended August 31, 2026 YoY Growth Net Sales $80.9 million
ALISO VIEJO, Calif., Oct. 7, 2026 /PRNewswire/ — Okami Medical, a medical technology company developing novel vascular embolization solutions, announced today that the U.S. FDA has granted an expanded indication for its LOBO® Vascular Occlusion System. The expanded indication extends the…
ClearRead Chest integration extends Riverain’s clinically proven cardiothoracic AI suite of solutions through a unified enterprise workflow designed to reduce fragmentation and accelerate action MIAMISBURG, Ohio, October 6, 2026 — Riverain Technologies, a leader in cardiothoracic imaging AI, today announced that its FDA-cleared ClearRead™ Chest suite will be available […]
Live case showcases successful below-the-knee revascularization with two MOTIV® scaffolds; late-breaking analysis shows higher efficacy endpoint rates with MOTIV versus balloon angioplasty in both Rutherford 4 and Rutherford 5 CLTI populations SAN DIEGO, Oct. 6, 2026 /PRNewswire/ — REVA…
SAN JOSE, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., the developer of proprietary volume-expanding shape memory polymer solutions for endovascular embolization, today announced that Brazil’s national health surveillance agency, ANVISA (Agência Nacional de Vigilância Sanitária), has granted authorization for the IMPEDE Embolization Plug, the IMPEDE-FX Embolization Plug, and the IMPEDE-FX RapidFill. The approval process was supported by Biomedical, which acts as Shape Memory Medical’s Br
MIAMI LAKES, Fla.–(BUSINESS WIRE)– #Cordis–Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at
